Day 3 of the health care negotiations: PD-1/L1 price war! Domestic quotations for domestic enterprises are less than 40,000/year

Medicine Network December 17th, December 16th, 2020 National Health Insurance Directory drug negotiations into the official day.
Two days before the talks, companies using drugs in the therapeutic fields of chronic diseases, eye diseases, liver and bile, tumors and mental illness took turn, while China Biopharmaceuticals' Arondini, Haussen Pharmaceuticals' Amethini and Baiji Shenzhou's Zebtini all appeared at the negotiating site today.
According to industry insiders, "soul cut price" did not reappear at this year's negotiating table, the atmosphere of price negotiations is moderate, the outflow price decline of more than 30% to 40%, compared with the previous year's 50% start of the decline has slowed.
And today's talks will undoubtedly fall on a price war over PD-1/L1, co-led by four multinational pharmaceutical companies, Mercer East, BMS, Roche and AstraZeneta, as well as three local pharmaceutical companies, Reuser Bio, Hengrui Pharmaceuticals and Baiji Shenzhou.
it is understood that seven PD-1/L1 drugs have all passed the formal review, this time in different groups of negotiations.
According to Sina Pharmaceuticals, this morning or mainly for the import of PD-1 negotiations, such as Merca East, AstraZeneta have entered the market, the afternoon is mainly for domestic PD-1 product negotiations, involving Hengrui Pharmaceuticals, Baiji Shenzhou, Junshi Biological and so on.
lowest offer for the K drug in Mesa East is about 100,000/year.
, according to people familiar with the matter, there are two domestic enterprises PD-1 offer of 30,000 / year, 37,000 / year.
as of press release, there has been no specific reduction and the outcome of the negotiations announced.
, the investment bank, said in a research note that Hengrui Pharmaceuticals, Baiji Shenzhou and Junshi Bio are expected to slash the price of PD-1 drugs by 60% to 80%, but imported PD-1 may not be included in the price reduction.
Transnational pharmaceutical companies: in exchange for significant price reduction opportunities remain doubtful as a new cancer treatment means, with PD-1/L1 mono-anti-acting immunotherapy drugs to rewrite the clinical status quo of tumor treatment, unsuperfected huge clinical needs greatly promote the rapid growth of this segment.
According to Evaluate Pharma, the global oncology market is expected to grow at a compound annual rate of 11.5 percent to $311.2 billion in 2026, while the global oncology drug market is expected to grow at a compound annual rate of 11.5 percent to $311.2 billion in 2026, while immuno oncology drugs will grow at a compound annual rate of $94.7 billion at a compound annual rate of 20.2 percent.
is the world's second largest pharmaceutical market after the United States, and will obviously become a must-have for pharmaceutical companies.
meters of intranet data show that although the first half of 2020 under the impact of the new crown epidemic, China's public medical institutions chemical drugs (including biological drugs) the vast majority of sub-category sales have declined, but anti-tumor and immunomodulants, the proportion of new drug sales compared with the first half of 2019, there is still a certain degree of growth, year-on-year growth rate of 13.81 percent.
industry sees a firm grip on the health-care negotiations as a catalyst for market release or a common choice for drug companies to co-opt.
2015, Mercadon's Pabli Pearl monoantigenic injection (K drug) became the first FDA-approved immuno-checkpoint inhibitor to go on the market.
with disruptive clinical data, K-drug has won the crown of global drug sales growth in recent years.
predicts that K-Drug will replace Shumeile as the new "Drug King" in 2026 with sales of $24.91 billion, nearly double the number of Navuliyu monoanti (O drugs) produced by BMS.
although the "OK drug" to the U.S. market at half price into the domestic, but the lower price of domestic PD-1 has now let it into the market.
this time, it remains to be seen whether multinational pharmaceutical companies such as Merca East and BMS will trade larger price reductions for the opportunity to release volume in the Chinese market in order to break through the siege of local products.
Some analysts believe that in the import drug prices are generally higher than domestic drugs in the market competition pattern, imported PD-1/L1 price reduction expectations may not meet the health care sector's hard price requirements, because the results of the health care negotiations are more concerned with the final price of the product than its price reduction.
At the same time, the pricing of multinational pharmaceutical companies in China will undoubtedly also have an impact on the global pricing of the product, how to balance and maintain the global price system is a difficult time, the industry is in the gold into the long-term import PD-1/L1 price reduction into health insurance is not optimistic.
local pharmaceutical companies: price negotiations to give more price space the industry generally believes that the import of PD-1/L1 products of the high probability of withdrawal makes the price competition between domestic innovative drugs more attractive.
In November 2019, Thyda Bio's Xindili monomatics fell by 63.73 percent, making them the only PD-1 singles to be included in the national health-care list, reducing annual costs for patients to less than $100,000.
despite the sharp drop in prices, Sales of Syndil's monoliths continued to volume, reaching 921 million yuan in the first half of 2020, almost equal to the product's full-year 2019 sales.
the third quarter of 2020, which is believed to be the third quarter of 2020, the product's sales in the third quarter alone have exceeded 600 million yuan, according to this market sales trend, the total annual sales may exceed 2 billion yuan.
it is worth noting that the entry into the health insurance of the letter Dili single resistance only three-line recurrence or refrover classic Hodgkin's lymphoma this adaptation, the significant release effect will intensify the price competition of the domestic PD-1 health care negotiations.
's number of adaptives has long been seen as a bargaining chip in the PD-1/L1 market, and the current carelli pearl single resistance with four adaptations is undoubtedly the industry's top concern.
in early October this year, Hengrui Pharmaceuticals offered a fourth-quarter promotion of 396,000 yuan in annual drug costs, from October 12 to the official announcement date of the national health care negotiations.
Guangdong Kai Securities analysis, from the point of termination of the promotion, Hengrui Pharmaceuticals through this promotion to the National Health Insurance Administration expressed a strong will to enter health insurance and bid negotiations.
in the industry's view, The "white cabbage price" given in advance by Karelli Pearl is bound to further test the quotation strategy of other local companies.
, however, the two offers, to see if the spread falls within the 15% range of the official estimate price of the price negotiations, may give the domestic PD-1 more room for quotations.
because it is a single product to calculate the price, separate negotiations, pharmaceutical companies only need to consider the health care sector's official estimate of prices, not into the fight with the price of the prisoner dilemma.
regardless of the outcome of the negotiations, Baiji Shenzhou, Junshi Bio and other related enterprises rose for two consecutive days, suggesting that the capital market has voted with the foot in favor of domestic PD-1 enterprises.
Industry insiders point out that the PD-1/L1 health care negotiations are of great concern because the trend in price negotiations will reflect to some extent the policy orientation of health care and how health insurance funds pay for it, which will directly affect the large number of clinical trials that have already begun and are under way, as well as the next clinical resource reallocation and investment decisions of drugs such as PD-1.
And from the decline in the health care negotiations based on innovative drugs, we can see that the trend of "implementing value-oriented strategic purchase of health insurance" in the health insurance sector has become clearer, and in the future, unsoiled clinical needs, significantly reduce the burden on patients, and improve the varieties of patients' clinical benefits will still receive strong support from health insurance policies and get better returns.
according to the medical insurance catalog adjustment program, the results of the current round of national medical insurance drug catalog access negotiations will be released in the near future, "Pharmaceutical Economics" will continue to maintain concern.
。